Dosage Charts Calculator Blends & Stacks Learn Blog Peptides
Open Calculator
Blog  ›  Retatrutide: The Triple-Action Peptide Reshaping Weight Research

Retatrutide: The Triple-Action Peptide Reshaping Weight Research

Jun 11, 2026 4 min GLP-1 / Metabolic
TL;DR
Retatrutide is a lab-made peptide that activates GLP-1, GIP, and glucagon receptors simultaneously. Phase 2 trials show it can reduce body weight by up to 24% over 48 weeks. Larger Phase 3 trials are now underway to confirm long-term safety and expand its uses.

What Is Retatrutide?

Think of your body's appetite and metabolism controls as a set of light switches. Most weight-loss drugs flip one switch. Retatrutide flips three at the same time.

It is a synthetic peptide — a short chain of amino acids — that activates three hormone receptors: GLP-1 (glucagon-like peptide-1), GIP (glucose-dependent insulinotropic polypeptide), and the glucagon receptor.[1] GLP-1 and GIP slow digestion and reduce appetite. The glucagon receptor nudges the body to burn more stored energy. Together, researchers call this a "triple agonist" approach.[3]

What Is Research Studying It For?

Scientists are investigating retatrutide across several metabolic conditions. The main areas are:

  • Obesity — reducing body weight in adults with a BMI of 30 or higher
  • Type 2 diabetes — lowering blood sugar (HbA1c) levels
  • Fatty liver disease — specifically metabolic dysfunction-associated steatotic liver disease (MASLD), the medical term for fat buildup in the liver
  • Obstructive sleep apnea and knee osteoarthritis — newer targets being explored in ongoing Phase 3 trials[6]

It is given as a once-weekly injection under the skin, similar to other peptides in its class.[2]

What Does the Evidence Show?

Weight Loss

The headline numbers come from a landmark 2023 Phase 2 trial published in The New England Journal of Medicine. Researchers followed 338 adults with obesity for 48 weeks.[1]

Here's what they found at 48 weeks, compared to placebo:

  • The 12 mg group lost an average of 24.2% of body weight — roughly one in four pounds
  • The 8 mg group lost an average of 22.8%
  • The 4 mg group lost an average of 17.1%
  • The placebo group lost just 2.1%

At the 8 mg and 12 mg doses, every single participant lost at least 5% of body weight, and more than 83% lost at least 15%.[1] Those are unusually strong results for a drug trial.

Blood Sugar Control

A separate Phase 2 trial published in The Lancet tested retatrutide in 281 people with type 2 diabetes. At 24 weeks, the highest dose (12 mg) cut HbA1c — a key measure of long-term blood sugar — by around 2%, a clinically meaningful drop. Participants also lost significant body weight alongside the blood sugar improvements.[4] Researchers noted that managing body weight is now considered just as important as hitting glucose targets in type 2 diabetes care.[4]

Liver Health

A 2024 Phase 2a trial in Nature Medicine looked at people with MASLD — fatty liver disease linked to metabolic problems. Retatrutide showed meaningful reductions in liver fat and markers of liver inflammation compared to placebo.[5] This is significant because few effective treatments currently exist for this condition.

Side Effects

The most common side effects were nausea, vomiting, and other gastrointestinal issues. These were dose-related — higher doses caused more symptoms — but most were mild to moderate. Starting at a lower dose and gradually stepping up reduced these effects.[1] Researchers also noted a temporary increase in heart rate that peaked around 24 weeks and then declined.[1]

Where Does Research Go Next?

Phase 2 trials test whether a drug works and what doses are safe. Phase 3 trials — the next, bigger step — test it in thousands of people across more diverse populations. The TRIUMPH program is a series of ongoing Phase 3 trials investigating retatrutide for obesity, obstructive sleep apnea, and knee osteoarthritis.[6] Researchers call it a potential "game changer" in metabolic pharmacotherapy, though long-term safety data are still being collected.[2]

How Do Researchers Track Doses?

Understanding how different doses perform is central to this research. Trial doses ranged from 0.5 mg all the way to 12 mg weekly, with careful escalation schedules.[1] Our retatrutide dosage chart maps out those studied dose ranges in an easy-to-read format. You can also use our calculator to explore the dose escalation protocols used in published trials — a useful reference when reading the research literature.

All content on this page is for research and educational purposes only. Nothing here constitutes medical advice. Always consult a qualified healthcare professional.

Sources

  1. Triple-Hormone-Receptor Agonist Retatrutide for Obesity - A Phase 2 Trial. — The New England journal of medicine, 2023. PMID 37366315.
  2. Retatrutide-A Game Changer in Obesity Pharmacotherapy. — Biomolecules, 2025. PMID 40563436.
  3. The power of three: Retatrutide's role in modern obesity and diabetes therapy. — European journal of pharmacology, 2024. PMID 39515565.
  4. Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes: a randomised, double-blind, placebo and active-controlled, parallel-group, phase 2 trial conducted in the USA. — Lancet (London, England), 2023. PMID 37385280.
  5. Triple hormone receptor agonist retatrutide for metabolic dysfunction-associated steatotic liver disease: a randomized phase 2a trial. — Nature medicine, 2024. PMID 38858523.
  6. Retatrutide for the treatment of obesity, obstructive sleep apnea and knee osteoarthritis: Rationale and design of the TRIUMPH registrational clinical trials. — Diabetes, obesity & metabolism, 2026. PMID 41090431.
See the dosage chart — Retatrutide
An investigational triple-agonist studied for weight and metabolic outcomes.
Retatrutide

FAQ

What makes retatrutide different from semaglutide or tirzepatide?
Semaglutide targets one receptor (GLP-1). Tirzepatide targets two (GLP-1 and GIP). Retatrutide targets all three — GLP-1, GIP, and the glucagon receptor. That extra glucagon action is thought to increase energy burning, which may explain the larger weight-loss numbers seen in early trials.[3] Phase 3 head-to-head comparisons are still underway.
How much weight loss did trials observe with retatrutide?
In a 48-week Phase 2 trial, participants receiving the highest dose (12 mg) lost an average of 24.2% of their body weight, compared to 2.1% in the placebo group. At the 8 mg and 12 mg doses, 100% of participants lost at least 5% of body weight.[1] These results are from a controlled research setting, not everyday clinical use.
Is retatrutide approved for medical use?
As of the latest available research, retatrutide has not yet received regulatory approval for clinical use. It is still in clinical trials. The TRIUMPH Phase 3 program is ongoing and aims to generate the large-scale safety and efficacy data required for regulatory review.[6] It is currently a research-use compound only.
What side effects were reported in retatrutide studies?
The most common side effects in trials were gastrointestinal — nausea, vomiting, and diarrhea. These were dose-related and generally mild to moderate. Starting at a lower dose (2 mg) and escalating slowly helped reduce these effects. A temporary increase in heart rate was also observed, peaking around 24 weeks before declining.[1]
For research and educational use only. Not medical advice.